Actinogen Medical Limited (ASX: ACW) - Share Price
- Current share price for ACW : $0.053
Actinogen Medical (ACW) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is an ASX-listed, biotechnology company developing a novel therapy for neurological diseases associated with dysregulated brain cortisol. There is an association between cortisol and detrimental changes in the brain, affecting cognitive function, harm to brain cells and long-term cognitive health.
ACW General Information +
| ASX Code | ACW |
| Website | N/A |
| Industry/Sector | Biotechnology |
| Market Cap ($M) | 205 |
| ACW Share Price | $0.053 |
| Day High | $0.054 |
| Day Low | $0.052 |
| Last Close | $0.053 |
| ACW Share Price Movement | - ( No change ) |
Prices as at 16:16, 8 Oct 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Actinogen Medical Limited (ACW) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Actinogen Medical Limited (ACW) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Actinogen Medical Limited (ACW) price-sensitive announcements
ACW - June 2026 Quarterly activity report & Appendix 4C
Actinogen Medical Limited announced its June 2026 quarterly activity report and Appendix 4
Actinogen Medical Limited (ACW)
30 Jul 2026 | 10:03 AM
30 Jul 2026 | 10:03 AM
ACW - Xanamem depression trial published in British J Psychiatry
Actinogen Medical Limited announced promising results from its Xanamem phase 2 depression
Actinogen Medical Limited (ACW)
20 Jul 2026 | 9:33 AM
20 Jul 2026 | 9:33 AM
ACW - ACW third positive XanaMIA trial data committee review
Actinogen Medical Limited announced the receipt of a third positive recommendation from th
Actinogen Medical Limited (ACW)
18 Jun 2026 | 8:57 AM
18 Jun 2026 | 8:57 AM
ACW - Actinogen receives positive scientific advice from EMA
Actinogen Medical Limited announced that it has received positive scientific advice from t
Actinogen Medical Limited (ACW)
28 May 2026 | 9:51 AM
28 May 2026 | 9:51 AM
Actinogen Medical Limited (ACW) Recent ASX Announcements
ACW Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2026A | -$15.38 | -$0.50 | -6.10% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2025A | -$14.73 | -$0.50 | -18.30% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$13.04 | -$0.60 | 5.30% | 0.00 | 0.00 | 0.00% | 0.0% |
ACW Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | ||
| Actinogen Medical Limited (ACW) | $209M | -0.0612 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| CSL Limited (CSL) | $85,746M | 0.7309 | -0.4379 | 0.0545 | 11.0696 | 19.6936 | 18.6751 | 2.38% | 2.35% | 2.43% |
| Mesoblast Limited (MSB) | $2,552M | -0.4380 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 307.0313 | 0.00% | 0.00% | 0.00% |
| PYC Therapeutics Limited (PYC) | $2,636M | -0.3971 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Telix Pharmaceuticals Limited (TLX) | $5,244M | -1.3893 | 0.0000 | -0.5227 | 0.0000 | 183.8902 | 385.2500 | 0.00% | 0.00% | 0.00% |
ACW Directors
| Name | Position | Start Date |
|---|---|---|
| Dr Steven Gourlay | Chief Executive Officer, Managing Director | 24 Mar 2021 |
| Dr Geoffrey Edward Duncan Brooke | Non-Executive Chairman, Non-Executive Director | 1 Mar 2017 |
| Dr George Morstyn | Non-Executive Director | 1 Dec 2017 |
| Mr Malcolm John McComas | Non-Executive Director | 4 Apr 2019 |
| Dr Nicki Vasquez | Non-Executive Director | 1 Mar 2023 |
Actinogen Medical Limited (ACW) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 9 Sep 2026 | BROOKE, Geoffrey | Exercise | Options | 237,029 | $0.038 | $8,888.590 |
| 9 Sep 2026 | BROOKE, Geoffrey | Buy | Indirect Shares | 237,029 | $0.038 | $8,888.590 |
| 28 Aug 2026 | BROOKE, Geoffrey | Issued | Direct Shares | 275,331 | $0.037 | $10,324.910 |
See all changes in directors' interest & trades for Actinogen Medical Limited (ACW) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
ACW Management
| Name | Position |
|---|---|
| Andrew Udell | Chief Commercial Officer |
| William Souter | Chief Financial Officer |
| Dana Hilt | Chief Medical Officer |
| Peter Webse | Company Secretary |
| Fujun Li | Head of Manufacturing |
| Michael Roberts | Investor Relations |
| Cheryl Townsend | Vice President of Clinical Operations |
ACW Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Actinogen Medical Limited (ACW). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 203,275,557 (5.47%) | Dr Steven Gourlay |
ACW Calendar of Events
| Date | Event |
|---|---|
| 26 August 2027 | Report (Annual) |
| 26 August 2027 | Report (Prelim) |
| 25 February 2027 | Report (Interim) |
| 30 November 2026 | AGM |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
